Baldirà J, Ruiz-Rodríguez JC, Wilson DC, et al. - Given there exist few validated biomarker or clinical score combinations that can distinguish between cases of infection and other non-infectious conditions after activation of an in-hospital sepsis code, and afford a precise severity evaluation of the corresponding host response, researchers undertook this prospective, observational analysis to define appropriate blood biomarker [MR-proADM (mid-regional proadrenomedullin), PCT (procalcitonin), C-reactive protein and lactate) or clinical score [Sequential Organ Failure Assessment and Acute Physiological and Chronic Health Evaluation II score] combinations to address this unmet clinical requirement. This study included patients activating the Vall d’Hebron University Hospital sepsis code within the emergency department (ED), hospital wards and ICU. Findings are suggestive of the potential utility of individual use of PCT and MR-proADM in assisting the accurate identification of patients with infection and in the evaluation of the overall severity of the host response, respectively. Additionally, the accurate identification of patients needing admission onto the ICU could be enabled by the use of MR-proADM, regardless of whether patients presented to the ED or were undergoing treatment on the ward. Thus, the facilitation of early treatment strategies after activation of an in-hospital sepsis code might be achieved by the initial measurement of both biomarkers.